Our Pricing

Wegovy Clinical Trial Results UK: Evidence-Based Weight Loss Data

Published on: June 03, 2026

Understanding wegovy clinical trial results uk is essential before starting treatment. As a UK-registered pharmacy with thousands of weight loss consultations completed, we've seen how clinical evidence helps patients make informed decisions. Wegovy (semaglutide 2.4mg) demonstrated remarkable efficacy across the landmark STEP trial programme, with participants achieving sustained weight reduction under medical supervision.

STEP Trial Programme: The Gold Standard for Wegovy Clinical Trial Results UK

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme represents the most comprehensive evaluation of semaglutide 2.4mg for weight management. Conducted across multiple countries including the UK, these phase 3 trials enrolled over 4,500 participants and established the evidence base that led to MHRA licensing in 2022 [1].

STEP 1, the pivotal trial, demonstrated that adults receiving Wegovy achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. Participants received weekly subcutaneous injections alongside lifestyle intervention, with two-thirds achieving at least 10% weight loss — a threshold associated with significant metabolic improvements.

What makes these wegovy clinical trial results uk particularly relevant is the real-world applicability. Trial participants had similar baseline characteristics to patients we assess daily: average BMI of 37.9 kg/m², many with comorbidities including hypertension and dyslipidaemia [1]. The results weren't achieved in a laboratory setting but through a practical combination of medication and behavioural support.

Breaking Down Wegovy Efficacy: What the Numbers Actually Mean

Clinical trial percentages can feel abstract until you understand what they represent in practice. An average 14.9% weight reduction for someone weighing 100kg translates to nearly 15kg lost — a clinically significant change associated with improved cardiovascular risk markers, better glycaemic control, and reduced joint loading [1][2].

The STEP trials also measured secondary endpoints beyond weight. Participants experienced average reductions in waist circumference of 13.5cm, improvements in blood pressure, and favourable changes in lipid profiles [1]. These cardiometabolic benefits matter enormously for long-term health outcomes, particularly for patients with obesity-related complications.

Importantly, weight loss wasn't linear. Most participants experienced gradual, sustained reduction over the 68-week period, with the steepest decline occurring between weeks 20 and 60 [1]. This pattern reflects how GLP-1 receptor agonists work — not as quick fixes, but as tools that support physiological changes in appetite regulation and satiety signalling.

Responder Rates: Who Benefits Most from Wegovy?

The STEP 1 trial showed that 86.4% of participants achieved at least 5% weight loss, whilst 66.1% reached the 10% threshold and 50.5% lost 15% or more [1]. These responder rates help set realistic expectations during consultations at Cured Pharmacy.

Factors associated with better outcomes included higher baseline BMI, younger age, and adherence to the dosing schedule [2]. However, even participants who didn't reach 15% typically experienced meaningful health improvements, demonstrating that Wegovy's benefits extend beyond the number on the scale.

STEP 2 Trial: Wegovy Clinical Trial Results UK for Type 2 Diabetes Patients

The STEP 2 trial specifically enrolled adults with type 2 diabetes and obesity, a population particularly relevant to UK prescribers given the high prevalence of both conditions [3]. Participants receiving Wegovy 2.4mg achieved average weight loss of 9.6% over 68 weeks, compared to 7.0% with semaglutide 1.0mg (the Ozempic dose) and 3.4% with placebo [3].

Whilst the absolute weight reduction was lower than in STEP 1, this cohort also experienced significant HbA1c improvements — average reduction of 1.6% from baseline [3]. This dual benefit makes Wegovy particularly valuable for patients managing both obesity and dysglycaemia, though prescribing decisions depend on individual clinical circumstances.

During consultations, our UK prescribers consider whether a patient has type 2 diabetes when discussing expected outcomes. The STEP 2 data provides realistic benchmarks and helps explain why diabetes status influences weight loss trajectories.

Long-Term Weight Maintenance: STEP 4 Extension Data

One critical question patients ask is whether weight loss persists. The STEP 4 trial addressed this by enrolling participants who had already lost weight on Wegovy for 20 weeks, then randomising them to continue treatment or switch to placebo [4].

Those continuing Wegovy maintained and extended their weight loss, achieving an additional 7.9% reduction over the subsequent 48 weeks [4]. In contrast, participants switched to placebo regained 6.9% of their body weight during the same period [4]. This withdrawal effect demonstrates that Wegovy supports ongoing weight management rather than providing a temporary fix.

At Cured Pharmacy, we discuss these findings openly during assessments. Semaglutide works by modulating appetite-regulating pathways, and discontinuation typically leads to gradual weight regain unless lifestyle changes are maintained. Long-term treatment may be appropriate for many patients, subject to ongoing clinical review.

Real-World Evidence Beyond Clinical Trials

Since MHRA approval, real-world data from UK prescribing has broadly aligned with trial outcomes. Observational studies show similar weight loss patterns, though with greater variability reflecting diverse patient populations and adherence levels [5].

Our clinical team at Cured Pharmacy monitors patient progress through follow-up consultations, allowing us to identify early non-responders and adjust treatment plans accordingly. This individualised approach, informed by trial evidence but adapted to real-world circumstances, optimises outcomes.

Safety Profile: Understanding Wegovy's Side Effects from Clinical Trials

No discussion of wegovy clinical trial results uk is complete without addressing tolerability. Across the STEP programme, the most common adverse events were gastrointestinal: nausea (44%), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These typically occurred during dose escalation and diminished over time.

Serious adverse events were uncommon but included gallbladder disorders (2.6% versus 1.2% with placebo) and pancreatitis in isolated cases [1]. The MHRA-approved prescribing information includes appropriate warnings, and our UK prescribers screen for contraindications including personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2.

Discontinuation rates due to adverse events were 7.0% with Wegovy versus 3.1% with placebo in STEP 1 [1]. Most patients who experienced side effects found them manageable, particularly when following the gradual dose escalation schedule. During consultations, we provide detailed guidance on managing gastrointestinal symptoms and when to seek medical review.

Starting Wegovy at Cured Pharmacy: Evidence-Based Treatment from £89

At Cured Pharmacy, we translate clinical trial evidence into practical patient care. Our UK-registered prescribers conduct thorough online assessments, evaluating whether Wegovy is clinically appropriate based on your BMI, medical history, and weight loss goals. Treatment starts from £79.00 with transparent pricing displayed before consultation.

Once approved, we dispense genuine UK-licensed Wegovy pens with full patient information and ongoing support. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures every prescription meets regulatory standards and aligns with NICE guidance on obesity management. You'll receive discreet packaging and can access our clinical team throughout your treatment journey.

The wegovy clinical trial results uk demonstrate what's possible under optimal conditions. Real-world outcomes depend on individual factors including adherence, lifestyle modifications, and metabolic variability. Our role is to provide the medication, clinical oversight, and evidence-based guidance that maximises your chances of success — just as the STEP trials showed is possible with proper medical support.

How to Begin Your Wegovy Assessment

Starting is straightforward: complete our free online consultation, which takes under 3 minutes. A UK prescriber reviews your submission, typically within 24 hours. If Wegovy is appropriate, we'll dispense your first prescription and arrange delivery. If not, we'll explain why and discuss alternative options.

Every prescription includes dosing instructions aligned with the STEP trial protocols: starting at 0.25mg weekly, gradually escalating to the maintenance dose of 2.4mg over 16-20 weeks. This gradual titration, proven effective in clinical trials, minimises side effects whilst optimising weight loss outcomes [1].

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., Lingvay, I., & STEP 2 Study Group. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., Kushner, R. F., & STEP 1 Study Group. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Clinical trial results represent average outcomes and individual results may vary.